Ac Immune Stock Today

ACIU Stock  USD 2.29  0.01  0.43%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
AC Immune is selling for under 2.29 as of the 16th of March 2025; that is 0.43 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.27. AC Immune has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
23rd of September 2016
Category
Healthcare
Classification
Health Care
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. The company has 98.94 M outstanding shares of which 1.16 M shares are presently shorted by private and institutional investors with about 5.31 trading days to cover. More on AC Immune

Moving together with ACIU Stock

  0.78VRCA Verrica PharmaceuticalsPairCorr
  0.64ENVB Enveric Biosciences Earnings Call Next WeekPairCorr
  0.71EVO Evotec SE ADRPairCorr

Moving against ACIU Stock

  0.5IVA Inventiva SaPairCorr
  0.44LLY Eli LillyPairCorr
  0.42ETON Eton PharmaceuticalsPairCorr
  0.37MGTX MeiraGTx Holdings PLC Downward RallyPairCorr
  0.32PBH Prestige Brand HoldingsPairCorr
  0.31PFE Pfizer IncPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

ACIU Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEO CoFounderAndrea Pfeifer
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.110.1183
Significantly Down
Slightly volatile
Total Current Liabilities105.9 M100.8 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total18.7 M17.8 M
Sufficiently Up
Slightly volatile
Total Assets184 M230.9 M
Significantly Down
Slightly volatile
Total Current Assets160.5 M172 M
Significantly Down
Slightly volatile
Debt Levels
AC Immune can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AC Immune's financial leverage. It provides some insight into what part of AC Immune's total assets is financed by creditors.
Liquidity
AC Immune currently holds 5.43 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. AC Immune has a current ratio of 13.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about AC Immune's use of debt, we should always consider it together with its cash and equity.

Depreciation

1.42 Million
AC Immune (ACIU) is traded on NASDAQ Exchange in USA. It is located in Building B, Lausanne, Switzerland, 1015 and employs 22 people. AC Immune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 226.58 M. AC Immune conducts business under Biotechnology sector and is part of Health Care industry. The entity has 98.94 M outstanding shares of which 1.16 M shares are presently shorted by private and institutional investors with about 5.31 trading days to cover. AC Immune currently holds about 154.15 M in cash with 65.84 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83.
Check AC Immune Probability Of Bankruptcy
Ownership Allocation
AC Immune secures a total of 98.94 Million outstanding shares. AC Immune shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check ACIU Ownership Details

ACIU Stock Institutional Holders

InstituionRecorded OnShares
Millennium Management Llc2024-12-31
119 K
Marshall Wace Asset Management Ltd2024-12-31
66.3 K
Geode Capital Management, Llc2024-12-31
64.1 K
Ubs Group Ag2024-12-31
49.7 K
Squarepoint Ops Llc2024-12-31
43.8 K
Two Sigma Investments Llc2024-12-31
40.8 K
Jane Street Group Llc2024-12-31
24.3 K
China Universal Asset Mgmt Co.ltd2024-12-31
21 K
Rpo Llc2024-12-31
18.7 K
Bvf Inc2024-12-31
19.5 M
Blackrock Inc2024-12-31
2.2 M
View AC Immune Diagnostics

AC Immune Historical Income Statement

At this time, AC Immune's Gross Profit is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 1.5 M in 2025, whereas Total Revenue is likely to drop slightly above 20.1 M in 2025. View More Fundamentals

ACIU Stock Against Markets

AC Immune Corporate Management

Oliver MDVP DevelopmentProfile
Matthias MaurerSVP CounselProfile
Nuno MDChief OfficerProfile
Christopher RobertsInterim FinProfile
Mark DantonExecutive IntelligenceProfile
Sonia PoliHead ScienceProfile
Piergiorgio DonatiChief OfficerProfile

Already Invested in AC Immune?

The danger of trading AC Immune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AC Immune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AC Immune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AC Immune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.